Skip to content
value.today

Tilray: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Pharmaceutical: $1.4 B to $6.1 B, median $3.2 BPrice to bookPrice to book of Pharmaceutical: $3.4 B to $13.4 B, median $6.6 B$0 M$3.6 B$7.2 B$10.9 B$14.5 BMarket value $241 M

Your own DCF model

A full discounted-cash-flow model of Tilray, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times Tilray's own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)TilrayApplied toValue (25th to 75th)Companies
Price to sales1.6× / 3.5× / 6.7×0.3×revenue $915 M$1.4 B to $6.1 B68
Price to book2.1× / 4.1× / 8.3×0.1×book equity $1.6 B$3.4 B to $13.4 B62

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to May 31, 2026$915 M$-121 M$-69 M——$-106 MSEC annual report (10-K, 20-F)
FY2024to May 31, 2025$821 M$-2.2 B$-95 M$33 M$-128 M—SEC annual report (10-K, 20-F)
FY2023to May 31, 2024$789 M$-245 M$-31 M$29 M$-60 M—SEC annual report (10-K, 20-F)
FY2022to May 31, 2023$627 M$-1.5 B$8 M$21 M$-13 M—SEC annual report (10-K, 20-F)
FY2021to May 31, 2022$628 M$-477 M$-177 M$34 M$-211 M$-230 MSEC annual report (10-K, 20-F)
FY2020to May 31, 2021$513 M$-271 M$-129 M$45 M$-174 M$-284 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $241 M on Oct 31, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.